Abstract: The present disclosure is concerned with biaryl aminomaleimide compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Compounds, compositions, and methods of treatment and prevention of Hepacivirus, Pestivirus, Flavivirus or Alphavirus infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of Hepacivirus, Pestivirus, Flavivirus or Alphavirus in an infected patient.

Abstract: Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.

Abstract: ?-NETA analogs are provided for the treatment of inflammatory disease.

Abstract: A shunt operable to be implanted on an eye is provided. The shunt includes a vein fluidic channel operable to be in fluid communication with an interior of the eye and operable to receive aqueous fluid from the interior of the eye. A body is fluidly coupled with the vein fluidic channel. A valve is disposed within the body and is operable to regulate intraocular pressure in the eye by opening and closing based on pressure from the aqueous fluid. A plurality of outlets are in fluid communication with the body opposite the vein fluidic channel in relation to the valve. The outlets are operable to release the aqueous fluid to the sclera of the eye.

Abstract: An ankle prosthesis can have a base and an upper hinge component that is pivotably attached to the base about an axis. First and second biasing elements can bias the upper hinge component in first and second rotational directions, respectively. At least one selectively extendable and retractable locking element can extend from one of the base and the upper hinge component and engage the other of the base and the upper hinge component to limit the pivotable movement of the upper hinge component.

Abstract: As an example, a walker includes a first leg pair, a second leg pair and a cross beam connecting the first and second leg pairs in a parallel, spaced apart relationship. Each leg pair includes a U-shaped tube defining a front leg and a rear leg. A front strut is telescopically movable within the front leg and extends outwardly therefrom. A rear strut is telescopically movable within the rear leg and extends outwardly therefrom. A mechanical linear actuator includes a rotating element adapted to rotate relative to at least one of the front leg or the rear leg. The rotating element includes an interface with a track on the respective strut relative to which the rotating element rotates, whereby rotational motion of the rotating element translates to corresponding linear motion of the strut.

Abstract: Provided are methods of treating an injury to the nervous system in a subject comprising administering to the subject an effective amount of boldine, a boldine analog, or a pharmaceutically-acceptable salt thereof. Also provided are methods of improving voluntary muscle control and methods of treating neuropathic pain in a subject having an injury to the nervous system. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed are compositions comprising an interferon-alpha binding protein and combined anti-retroviral therapy (cART). In some aspects, the interferon-alpha binding protein is B18R. In some aspects, the compositions further comprise a pharmaceutically acceptable carrier. Disclosed are methods of treating a subject with HIV associated neurogenerative disorder (HAND) comprising administering a therapeutically effective amount of B18R and cART. Disclosed are methods of reversing behavioral abnormalities in subjects having HAND comprising administering a therapeutically effective amount of B18R.

Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.

Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.

Abstract: Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

Abstract: The present invention provides synthetic methods and novel intermediates in the preparation of 3-aryl Endochin-like quinolone (ELQ) compounds.

Abstract: This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.

Abstract: A trunk control system having a harness assembly and a flexion control assembly. The harness assembly has a backrest member and a harness secured to the backrest member. The backrest member is configured to be moveably coupled to a wheelchair. The backrest member is selectively moveable about and between a fully retracted position and a fully extended position. The harness cooperates with the backrest member to define a receiving space for receiving at least a portion of a torso of a wheelchair user. The flexion control assembly is coupled to the backrest member of the harness assembly. The flexion control assembly is configured to selectively permit or restrict movement of the backrest member about and between the fully retracted position and the fully extended position.

Abstract: The present invention is directed to wound healing scaffolds cografted with a population of stem cells, wherein the population of stem cells are ABCB5+ stem cells. The scaffolds are, for instance, collagen glycosaminoglycan scaffolds.

Abstract: A bench assembly can be for use in a bathtub for showering. The bench assembly can comprise a frame that is configured to sit within a bathtub. A bench can be coupled to the frame. A pivotable platform assembly can comprise a platform support structure pivotably coupled to the frame and a platform coupled to the platform support structure. The pivotable platform assembly can be configured to bias against an upper rim of the bathtub.

Abstract: The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention provides methods for cancers associated with a TERT promoter mutation in a subject. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of an agent that specifically reduces or inhibits GA binding protein transcription factor beta subunit 1 long isoform (GABPBIL) expression or function.

Abstract: The methods and systems provided can automatically determine an Arteriolar-to-Venular diameter Ratio, AVR, in blood vessels, such as retinal blood vessels and other blood vessels in vertebrates. The AVR is an important predictor of increases in the risk for stroke, cerebral atrophy, cognitive decline, and myocardial infarct.